Imaging features associated with disease progression after stereotactic ablative radiotherapy for stage i non-small-cell lung cancer

Clinical Lung Cancer

Volumn 15, Issue 4, 2014, Pages

  Shultz, David B ^a   Trakul, Nicholas ^a   Abelson, Jonathan A ^a   Murphy, James D ^a   Maxim, Peter G ^a   Le, Quynh Thu ^a   Loo, Billy W ^a   Diehn, Maximilian ^a,b  

^a STANFORD CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Early stage; FDG PET; Prognostic; SABR; Stereotactic body radiation therapy (SBRT)

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; MIDDLE AGED; OVERALL SURVIVAL; PLEURA; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMIC THERAPY; THORAX WALL; TUMOR VOLUME; VERY ELDERLY; ABLATION THERAPY; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC IMAGING; DISEASE COURSE; LUNG NEOPLASMS; METASTASIS; MORTALITY; PROGNOSIS; RADIOSURGERY; SURVIVAL;

ABLATION TECHNIQUES; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOSURGERY; SURVIVAL ANALYSIS;

EID: 84903267743     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.12.011     Document Type: Article

References (32)

1. S. Senthi, F.J. Lagerwaard, C.J. Haasbeek, B.J. Slotman, and S. Senan Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis Lancet Oncol 13 2012 802 809
2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Small Cell Lung Cancer Version 2.2013. Available at: http://www.nccn.org/ professionals/physician-gls/pdf/nscl.pdf. Accessed: October 3, 2013.
3. D. Palma, and S. Senan Stereotactic radiation therapy: changing treatment paradigms for stage I non-small-cell lung cancer Curr Opin Oncol 23 2011 133 139
4. H. Vesselle, A. Salskov, and E. Turcotte et al. Relationship between non-small-cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index J Thorac Oncol 3 2008 971 978
5. H. Saito, M. Oshima, R. Kiuchi, K. Watanabe, K. Kitagawa, and S. Masuda Relationship between pleural indentation on computed tomography scans and pleural invasion in small peripheral lung cancer of 2 cm in size or less [in Japanese] Kyobu Geka 62 2009 767 770 discussion 770-2
6. N. Trakul, C.N. Chang, and J. Harris et al. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors Int J Radiat Oncol Biol Phys 84 2012 231 237
7. C. Park, L. Papiez, S. Zhang, M. Story, and R.D. Timmerman Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy Int J Radiat Oncol Biol Phys 70 2008 847 852
8. P. Lee, D.K. Weerasuriya, and P.W. Lavori et al. Metabolic tumor burden predicts for disease progression and death in lung cancer Int J Radiat Oncol Biol Phys 69 2007 328 333
9. K. Imai, Y. Minamiya, and K. Ishiyama et al. Use of CT to evaluate pleural invasion in non-small-cell lung cancer: measurement of the ratio of the interface between tumor and neighboring structures to maximum tumor diameter Radiology 267 2013 619 626
10. R.L. Camp, M. Dolled-Filhart, and D.L. Rimm X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut point optimization Clin Cancer Res 10 2004 7252 7259
11. A. Ketchedjian, B.D. Daly, and H.C. Fernando et al. Location as an important predictor of lymph node involvement for pulmonary adenocarcinoma J Thorac Cardiovasc Surg 132 2006 544 548
12. B. Besse, and T. Le Chevalier Developments in the treatment of early NSCLC: when to use chemotherapy Ann Oncol 23 suppl 10 2012 x52 x59
13. G.M. Strauss, J.E. Herndon 2nd, and M.A. Maddaus et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups J Clin Oncol 26 2008 5043 5051
14. S. Heon, and B.E. Johnson Adjuvant chemotherapy for surgically resected non-small-cell lung cancer J Thorac Cardiovasc Surg 144 2012 S39 S42
15. K. Kawaguchi, S. Mori, N. Usami, T. Fukui, T. Mitsudomi, and K. Yokoi Preoperative evaluation of the depth of chest wall invasion and the extent of combined resections in lung cancer patients Lung Cancer 64 2009 41 44
16. G. Krdzalic, D. Mesic, and E. Iljazovic et al. Mediastinal lymph node metastasis pattern in clinically N0 non-small-cell lung cancer patients who underwent surgical resection Med Arh 64 2010 332 334
17. T. Berghmans, M. Dusart, and M. Paesmans et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small-cell lung cancer (NSCLC): a systematic review and metaanalysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project J Thorac Oncol 3 2008 6 12
18. K. Clarke, M. Taremi, and M. Dahele et al. Stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer (NSCLC): is FDG-PET a predictor of outcome? Radiother Oncol 104 2012 62 66
19. D.S. Lee, Y.S. Kim, and R. Yoo Ie et al. Long-term clinical experience of high-dose ablative lung radiotherapy: high pre-treatment [18F] fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome Lung Cancer 80 2013 172 178
20. J.Y. Chang, H. Liu, and P. Balter et al. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer Radiat Oncol 7 2012 152
21. J.A. Abelson, J.D. Murphy, and N. Trakul et al. Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy Lung Cancer 78 2012 219 224
22. M.J. Burdick, K.L. Stephans, C.A. Reddy, T. Djemil, S.M. Srinivas, and G.M. Videtic Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy Int J Radiat Oncol Biol Phys 78 2010 1033 1039
23. D.J. Hoopes, M. Tann, and J.W. Fletcher et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer Lung Cancer 56 2007 229 234
24. A. Joshi, R.A. Koeppe, and J.A. Fessler Reducing between scanner differences in multi-center PET studies Neuroimage 46 2009 154 159
25. B. Goodgame, A. Viswanathan, and C.R. Miller et al. A clinical model to estimate recurrence risk in resected stage I non-small-cell lung cancer Am J Clin Oncol 31 2008 22 28
26. Y. Chen, W. Guo, Y. Lu, and B. Zou Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small-cell lung cancer: long-term results and efficacy of adjuvant chemotherapy Radiother Oncol 88 2008 351 358
27. J.K. Salama, and E.E. Vokes New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer J Clin Oncol 31 2013 1029 1038
28. R. Onimaru, M. Fujino, and K. Yamazaki et al. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy Int J Radiat Oncol Biol Phys 70 2008 374 381
29. F. Baba, Y. Shibamoto, and H. Ogino et al. Clinical outcomes of stereotactic body radiotherapy for stage I non-small-cell lung cancer using different doses depending on tumor size Radiat Oncol 5 2010 81
30. I.J. Chetty, S. Devpura, and D. Liu et al. Correlation of dose computed using different algorithms with local control following stereotactic ablative radiotherapy (SABR)-based treatment of non-small-cell lung cancer Radiother Oncol 109 2013 498 504
31. N. Andratschke, F. Zimmermann, and E. Boehm et al. Stereotactic radiotherapy of histologically proven inoperable stage I non-small-cell lung cancer: patterns of failure Radiother Oncol 101 2011 245 249
32. J.D. Bradley, I. El Naqa, R.E. Drzymala, M. Trovo, G. Jones, and M.D. Denning Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant Int J Radiat Oncol Biol Phys 77 2010 1146 1150